Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-murine PD-1 is a monoclonal antibody used in preclinical research to block the Programmed Cell Death Protein 1 (PD-1) receptor in mouse models. It is a standard tool for investigating the effects of immune checkpoint blockade in syngeneic tumor models, such as the AB1B mesothelioma model. By preventing the interaction between PD-1 and its ligands, PD-L1 and PD-L2, the antibody enhances T-cell mediated anti-tumor activity. In the provided context, it was used both as a monotherapy and in combination with an ADORA2B inhibitor (TT4) to demonstrate synergistic anti-tumor effects and increased immune cell infiltration in mesothelioma-bearing mice.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-murine PD-1.